MRESD - M2Bio Sciences Division M2Biome Cardiometabolic Health Launches Website
(NewsDirect)
Institute ofBiomedical Research (OTC: MRES) ("M2Bio Sciences'' or the"Company"), a bioceutical company focused on alternativeplant-based cannabinoids and mental health therapeutic research ispleased to share the following update:
M2Biome, a division of M2Bio Sciences, ispleased to announce the launch of its website. The website has beenset up to serve healthcare professionals and health consumers alike.Sections include a health blog, called ‘Digestible Facts’,educational resources, recipes, and more.
One key feature of the website includes adiabetes screening tool on the home page, which will notify people oftheir risk of having undiagnosed type 2 diabetes (T2DM) and promptthem to undergo further tests. This is also a valuable tool forhighlighting the lifestyle changes that are needed to reduce the riskof developing T2DM and other non-communicable diseases that havesimilar underlying pathophysiology. Part of the M2Biome mission is toprovide education on health and nutrition, and create awareness of therisk of disease.
“The prevalence of undiagnosed diabetes in South Africa isestimated to be in the region of 45%. Unfortunately, many people areonly diagnosed once they have developed complications, which has ahuge impact on the quality of life and the cost of managing theseindividuals. As type 2 diabetes is largely preventable and manageable,I am passionate about creating awareness of risk. I am currentlyworking on further validating the African Diabetes Risk Score to makeit more generalizable in the South African population. ”, says Nicola Royce, Managing Director of M2Biome.
The recipe section willbe the ultimate user-friendly guide to very practical andeasy-to-prepare healthy dishes. Each recipe will also serve as anopportunity to educate on the nutritional content of the dish. Youwill also learn how to make use of simple cooking methods to get themost out of the least ingredients. The recipes are divided intobreakfast, lunch, dinner, dessert, snacks, condiments, and drinks foreasy access to your needs. Icons have been developed to guide you inmeeting your special dietary requirements with confidence.
"Food should befun, functional, and user-friendly. If you cannot make it, you cannoteat it. It is unacceptable for good produce to go to waste because itis too difficult to make the most of it. Never should any ingredientbe used or abused to end up being unhealthy. Cooking should be easyand done in such a way that the end result ismulti-beneficial. ", says Wilna Eksteen, CardiometabolicProduct Developer.
M2Biome is also developing a Registered Dietitian database forhealth consumers to seek individualized treatment. While there aresome basic principles when it comes to nutrition, there is no‘blanket’ approach when applying medical nutrition therapy forvarious conditions. It is important for people to consult a RegisteredDietitian to receive an individualized and tailored approach thattakes religious requirements, life cycle stage, and dietaryrequirements and preferences into account.
‘’In line with an individualizedapproach, M2Biome will be incorporating Artificial Intelligence andMachine Learning for better patient outcomes. Machine learning takeslarge amounts of data to uncover patterns and insights related todietary choices, health outcomes, and nutritional needs. Leveragingmachine learning algorithms assists with developing personalisednutrition recommendations based on individual factors such as age,gender, activity level, and health conditions, leading to moretailored and effective dietary interventions. This will all beincorporated into an interactive model that assists individuals with‘health nudges’ by generating meal plans, recipes to go with thesemeal plans, and even recommendations of where and what to eat, basedon their requirements. Individuals can insert their daily activities,which will be documented and made available to their healthcarepractitioners. Any health developments are recorded, which assistswith adjusting recommendations and advising on any drug and nutrientinteractions that should be remedied. This is all really the tip ofthe iceberg, and the sky appears to be the limit with all of the‘smart’ technology we have in our lives today and how it can beused to connect the dots to help us lead healthier lives. This newinteractive platform is going to be epic!’’ says JeffRobinson, M2Bio Sciences CEO.
About Institute of Biomedical Research Corp./ DBAM2Bio Sciences
Institute of Biomedical Research Corp, is a nutraceuticalbiotechnology company focused on alternative plant-based cannabinoidsand psilocybin medical research that develops and commercializes arange of CBD and mushrooms-based products under Dr. AnnaRx™,Medspresso™, and Liviana™ brands. In addition, our research andclinical trials with psilocybin are aimed at new therapies that willhelp patients who suffer from alcohol addiction, mental illness, andcardiovascular diseases. Our mission is to advance botanical-basedmedicine to the forefront by deploying best-practice science andmedicine, clinical research, and emerging technologies. The Company istraded on the Over-the-Counter Bulletin Board of NASDAQ under thetrading symbol "MRES".
Contact:
Website: www.m2biome.com
E-mail: m2biome@m2bio.co
Phone: +27 72 3332148
Visit us onsocial media:
Forward-LookingStatements:
SafeHarbour Statement: In addition to historical information, this pressrelease may contain statements that constitute forward-lookingstatements within the meaning of the Securities Act of 1933 and theSecurities Exchange Act of 1934, as amended by the Private SecuritiesLitigation Reform Act of 1995. Forward-looking statements contained inthis press release include the intent, belief, or expectations of theCompany and members of its management team with respect to theCompany's future business operations and the assumptions uponwhich such statements are based. Prospective investors are cautionedthat any such forward-looking statements are not guarantees of futureperformance, involve risks and uncertainties, and that actual resultsmay differ materially from those contemplated by such forward-lookingstatements. Factors that could cause these differences to include, butare not limited to, failure to complete anticipated sales undernegotiations, lack of revenue growth, client discontinuances, failureto realize improvements in performance, efficiency, and profitability,and adverse developments with respect to litigation or increasedlitigation costs, the operation or performance of the Company'sbusiness units or the market price of its common stock. Additionalfactors that could cause actual results to differ materially fromthose contemplated within this press release can also be found on theCompany's website. The Company disclaims any responsibility toupdate any forward-looking statements.
ContactDetails
Institute of Biomedical Research Corp.
CompanyWebsite
Copyright (c) 2023 TheNewswire - All rights reserved.